PharmaCyte Biotech (OTCMKTS:PMCB) and Ocugen (NASDAQ:OCGN) Critical Review
PharmaCyte Biotech (OTCMKTS:PMCB) and Ocugen (NASDAQ:OCGN) Critical Review
Ocugen currently has a consensus price target of $4.80, suggesting a potential upside of 499.85%. Given Ocugen's higher probable upside, research analysts clearly believe Ocugen is more favorable than PharmaCyte Biotech. Ocugen (NASDAQ:OCGN – Get Rating) and PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.
Ocugen（納斯達克股票代碼：OCGN — 獲取評級）和Pharmacyte Biotech（OTCMKTS: PMCB — 獲取評級）都是小型醫療公司，但哪隻是優勢股？我們將根據兩家公司的盈利能力、估值、風險、分析師建議、收益、股息和機構所有權進行比較。
Institutional & Insider Ownership
機構和內部所有權
37.5% of Ocugen shares are held by institutional investors. Comparatively, 33.2% of PharmaCyte Biotech shares are held by institutional investors. 2.8% of Ocugen shares are held by insiders. Comparatively, 5.6% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
37.5％的Ocugen股份由機構投資者持有。相比之下，33.2％的Pharmacyte Biotech股票由機構投資者持有。2.8％的Ocugen股份由內部人士持有。相比之下，Pharmacyte Biotech的5.6％股票由內部人士持有。強大的機構所有權表明，大型基金經理、捐贈基金和對沖基金認爲，從長遠來看，公司的表現將超過市場。
Analyst Recommendations
分析師建議
This is a summary of current recommendations for Ocugen and PharmaCyte Biotech, as reported by MarketBeat.com.
據Marketbeat.com報道，這是目前對Ocugen和Pharmacyte Biotech的建議摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocugen | 0 | 0 | 5 | 0 | 3.00 |
| PharmaCyte Biotech | 0 | 0 | 0 | 0 | N/A |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 奧庫根 | 0 | 0 | 5 | 0 | 3.00 |
| Pharmacyt | 0 | 0 | 0 | 0 | 不適用 |
Ocugen currently has a consensus price target of $4.80, suggesting a potential upside of 499.85%. Given Ocugen's higher probable upside, research analysts clearly believe Ocugen is more favorable than PharmaCyte Biotech.
Ocugen目前的共識目標價爲4.80美元，這表明潛在的上漲空間爲499.85％。鑑於Ocugen的可能上行空間更高，研究分析師顯然認爲Ocugen比Pharmacyte Biotech更有利。
Profitability
盈利能力
This table compares Ocugen and PharmaCyte Biotech's net margins, return on equity and return on assets.
該表比較了Ocugen和Pharmacyte Biotech的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Ocugen | N/A | -76.64% | -65.51% |
| PharmaCyte Biotech | N/A | -6.71% | -6.64% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 奧庫根 | 不適用 | -76.64% | -65.51% |
| Pharmacyt | 不適用 | -6.71% | -6.64% |
Earnings and Valuation
收益和估值
This table compares Ocugen and PharmaCyte Biotech's top-line revenue, earnings per share and valuation.
該表比較了Ocugen和Pharmacyte Biotech的收入收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ocugen | $42.62 million | 4.25 | -$81.35 million | ($0.38) | -2.11 |
| PharmaCyte Biotech | N/A | N/A | -$4.24 million | ($0.26) | -11.35 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
| 奧庫根 | 4262 萬美元 | 4.25 | -8135 萬美元 | (0.38 美元) | -2.11 |
| Pharmacyt | 不適用 | 不適用 | -424 萬美元 | (0.26 美元) | -11.35 |
PharmaCyte Biotech has lower revenue, but higher earnings than Ocugen. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.
Pharmacyte Biotech的收入較低，但收益高於Ocugen。Pharmacyte Biotech的市盈率低於Ocugen，這表明它目前是這兩隻股票中更實惠的一隻。
Volatility & Risk
波動性與風險
Ocugen has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.
Ocugen的beta值爲3.85，這表明其股價的波動性比標準普爾500指數高285％。相比之下，Pharmacyte Biotech的beta值爲-0.03，這表明其股價的波動性比標準普爾500指數低103％。
Summary
摘要
Ocugen beats PharmaCyte Biotech on 6 of the 11 factors compared between the two stocks.
比較兩隻股票的11個因素中，Ocugen在6個因素上擊敗了Pharmacyte Biotech。
About Ocugen
關於 Ocugen
(Get Rating)
（獲取評級）
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Ocugen, Inc. 是一家生物製藥公司，從事治療眼部疾病的療法的開發和商業化。其候選產品線包括 OCU400、OCU410、OCU200 和 COVAXIN。該公司的修改基因治療平臺致力於治療視網膜疾病，包括色素性視網膜炎、leber先天性黑蒙症和乾性年齡相關性黃斑變性。該公司由 Shankar Musunuri 和 Uday B. Kompella 於 2013 年創立，總部位於賓夕法尼亞州馬爾文。
About PharmaCyte Biotech
關於 Pharmacyte
(Get Rating)
（獲取評級）
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
Pharmacyte Biotech, Inc. 是一家臨牀階段的生物技術公司，從事癌症和糖尿病治療的開發和商業化。它專注於一種名爲Cell-in-a-box的基於纖維素的專有活細胞封裝技術，該技術將用作開發無法手術的胰腺癌和其他實體癌腫瘤以及糖尿病治療的平臺。該公司成立於1996年10月28日，總部位於內華達州拉斯維加斯。
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Ocugen Daily 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Ocugen及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。
